[go: up one dir, main page]

PL371593A1 - Sposób wytwarzania leków w formie homogenicznych,suszonych rozpyłowo, stałych, bezpostaciowych dyspersji z zastosowaniem dysz ciśnieniowych - Google Patents

Sposób wytwarzania leków w formie homogenicznych,suszonych rozpyłowo, stałych, bezpostaciowych dyspersji z zastosowaniem dysz ciśnieniowych

Info

Publication number
PL371593A1
PL371593A1 PL03371593A PL37159303A PL371593A1 PL 371593 A1 PL371593 A1 PL 371593A1 PL 03371593 A PL03371593 A PL 03371593A PL 37159303 A PL37159303 A PL 37159303A PL 371593 A1 PL371593 A1 PL 371593A1
Authority
PL
Poland
Prior art keywords
dried solid
pressure nozzles
solid amorphous
amorphous drug
homogeneous spray
Prior art date
Application number
PL03371593A
Other languages
English (en)
Inventor
Ronald Arthur Beyerinck
Roderick Jack Ray
Daniel Elmont Dobry
Dana Marie Settell
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371593(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL371593A1 publication Critical patent/PL371593A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Glanulating (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Disintegrating Or Milling (AREA)
PL03371593A 2002-02-01 2003-01-20 Sposób wytwarzania leków w formie homogenicznych,suszonych rozpyłowo, stałych, bezpostaciowych dyspersji z zastosowaniem dysz ciśnieniowych PL371593A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35398602P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
PL371593A1 true PL371593A1 (pl) 2005-06-27

Family

ID=27663274

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03371593A PL371593A1 (pl) 2002-02-01 2003-01-20 Sposób wytwarzania leków w formie homogenicznych,suszonych rozpyłowo, stałych, bezpostaciowych dyspersji z zastosowaniem dysz ciśnieniowych

Country Status (20)

Country Link
US (1) US7780988B2 (pl)
EP (1) EP1469830A2 (pl)
JP (1) JP2005523260A (pl)
KR (1) KR100758045B1 (pl)
CN (1) CN1787808A (pl)
AR (1) AR038369A1 (pl)
AU (1) AU2003239463B2 (pl)
BR (1) BR0307515A (pl)
CA (1) CA2474958A1 (pl)
GT (1) GT200300024A (pl)
MX (1) MXPA04007435A (pl)
PA (1) PA8565401A1 (pl)
PE (1) PE20030804A1 (pl)
PL (1) PL371593A1 (pl)
RS (1) RS67304A (pl)
RU (1) RU2288703C2 (pl)
TW (1) TW200404576A (pl)
UY (1) UY27645A1 (pl)
WO (1) WO2003063821A2 (pl)
ZA (1) ZA200405971B (pl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
CN1787808A (zh) 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CA2560984A1 (en) 2004-06-01 2005-12-15 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparation of amorphous form of a drug
DK2502911T3 (en) 2004-06-24 2017-06-06 Vertex Pharma Modulators of ATP-binding cassette transporters
EP1817315A1 (en) 2004-12-01 2007-08-15 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Processes for producing crystalline macrolides
US9265731B2 (en) 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CN101272769B (zh) 2005-07-28 2013-04-24 Isp投资有限公司 生物利用度提高的苯醌类化合物
CN101304970A (zh) * 2005-12-21 2008-11-12 卫材R&D管理有限公司 1，2-二氢吡啶化合物的无定形物
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
BRPI0707584A2 (pt) 2006-02-09 2011-05-10 Merck & Co Inc composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
MX2008015686A (es) 2006-06-06 2009-01-12 Tibotec Pharm Ltd Procedimiento para preparar formulaciones secadas por aspersion de etravirina.
US8834929B2 (en) 2006-07-21 2014-09-16 Bend Research, Inc. Drying of drug-containing particles
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
EP2093225A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing crystalline eletriptan hydrobromide form ß
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
RU2543714C2 (ru) 2009-03-20 2015-03-10 Вертекс Фармасьютикалз Инкорпорейтед Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
EP2813220A3 (en) 2010-04-09 2015-06-17 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
UA108886C2 (ru) 2010-06-09 2015-06-25 Еббві Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
AU2012204462A1 (en) 2011-01-05 2013-07-11 Hospira, Inc. Spray drying vancomycin
TWI520732B (zh) * 2011-01-18 2016-02-11 輝瑞有限公司 固體分子分散液
PT106063B (pt) * 2011-12-19 2017-05-30 Inst Superior Tecnico Minociclina cristalina termorresistente produzida por recristalização com dióxido de carbono
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
RU2699358C2 (ru) 2012-05-31 2019-09-05 Мерк Шарп И Доум Корп. Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
CN105358535B (zh) * 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
BR112014011938B1 (pt) 2013-01-31 2021-03-16 Gilead Pharmasset Llc composição farmacêutica na forma de um comprimido com uma combinação de dose fixa de dois compostos antivirais, forma de dosagem farmacêutica compreendendo a referida composição e uso da referida composição
WO2014121137A2 (en) 2013-02-01 2014-08-07 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
EP4066841A1 (en) 2013-03-14 2022-10-05 University of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
CN103694903B (zh) * 2013-12-02 2015-07-01 南通瑞普埃尔生物工程有限公司 一种瞬干胶粘剂及其制备方法
JP6505705B2 (ja) * 2013-12-05 2019-04-24 アルライズ バイオシステムズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 経口投与用製剤の製造方法
JP6649378B2 (ja) * 2014-07-25 2020-02-19 ローラン・ファーマシューティカルズ フェンレチニドの固体経口処方物
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
WO2016067132A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
WO2016090105A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Anticancer compositions
SG11201704267VA (en) * 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
RU2585023C1 (ru) * 2014-12-18 2016-05-27 Общество с ограниченной ответственностью "Нанолек" Способ гранулирования
EP3307246A1 (en) 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
BR112021001170A2 (pt) 2018-07-30 2021-04-27 Chugai Seiyaku Kabushiki Kaisha dispersão sólida de derivado de hidantoína
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
JP2022554352A (ja) * 2019-11-06 2022-12-28 マンカインド コーポレイション クロファジミンの組成物、それを含む組合せ、その調製プロセス、それを含む使用及び処置方法
WO2021138485A1 (en) 2019-12-30 2021-07-08 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
KR20230097021A (ko) 2020-09-29 2023-06-30 선전 파마신 컴퍼니 리미티드 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
DE2201111A1 (de) 1971-01-19 1972-07-27 Niro Atomizer As Zerstaeubungstrocknungsvorrichtung zur Herstellung von Pulver,z.B. Milchpulver
IT1025765B (it) 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
DE2741196A1 (de) * 1977-09-13 1979-03-15 Bayer Ag Verfahren zur herstellung von perlpolymeren
US4187617A (en) 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
US6068859A (en) 1994-05-06 2000-05-30 Pfizer Inc. Controlled-release dosage forms of Azithromycin
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CN1787808A (zh) 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CA2472028C (en) * 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus

Also Published As

Publication number Publication date
AU2003239463B2 (en) 2007-10-18
AR038369A1 (es) 2005-01-12
EP1469830A2 (en) 2004-10-27
BR0307515A (pt) 2004-12-07
MXPA04007435A (es) 2004-10-11
KR100758045B1 (ko) 2007-09-11
US7780988B2 (en) 2010-08-24
JP2005523260A (ja) 2005-08-04
PA8565401A1 (es) 2003-12-10
RU2004123639A (ru) 2005-04-20
ZA200405971B (en) 2006-05-31
WO2003063821A2 (en) 2003-08-07
GT200300024A (es) 2003-09-22
CN1787808A (zh) 2006-06-14
TW200404576A (en) 2004-04-01
PE20030804A1 (es) 2003-09-19
US20030185893A1 (en) 2003-10-02
UY27645A1 (es) 2003-09-30
RU2288703C2 (ru) 2006-12-10
RS67304A (en) 2006-10-27
WO2003063821A3 (en) 2003-11-13
CA2474958A1 (en) 2003-08-07
KR20040083491A (ko) 2004-10-02

Similar Documents

Publication Publication Date Title
PL371593A1 (pl) Sposób wytwarzania leków w formie homogenicznych,suszonych rozpyłowo, stałych, bezpostaciowych dyspersji z zastosowaniem dysz ciśnieniowych
IL162819A0 (en) Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AU2003273831A1 (en) Method for making ophthalmic devices
WO2007002052A8 (en) Apparatus and method for injecting a pharmaceutical
AU2003209702A1 (en) Apparatus for electrosurgery
AU2003206898A1 (en) Method for rate matching
IL175655A0 (en) Method for making pharmaceutical multiparticulates
AU2003290465A1 (en) Spraying device and method for fluidised bed granulation
AU2003222056A1 (en) Process for extracting biomedical devices
EP1550725A4 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE
AU2003297367A1 (en) Process for preparing pharmaceutical formulations using supercritical fluids
AU2003226810A1 (en) Method for producing methyl formate
AU2003284758A1 (en) Method for preparing oltipraz
AU2003289650A1 (en) An apparatus for producing active water
AU2003245509A1 (en) Method and apparatus for producing non-planar formed parts using compaction molding compounds, and parts formed using same
AU2003206964A1 (en) Method for producing riboflavin
AU2003289203A1 (en) Solid-state imaging device and method for producing solid-state imaging device
IL164901A (en) Process for preparing optically active beta-aminoketones
AU2003273863A1 (en) Method for producing polyether alcohols
GB2418540B (en) A method for forming a joint
AU2003275898A1 (en) Process for preparing an adenovirus-containing preparation
AU2003255729A1 (en) Spray apparatus
HK1080396A1 (en) Method for producing a biologicaly active substance
AU2003234352A1 (en) Process for preparing apigenin-7-o-%a-d-glucuronide from clerodendron trichotomum folium
AU2003256158A1 (en) Process for preparing biocompatible polyurea

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)